AIN
Next-Gen Exosome Biotech

Next-Gen Exosome Biotech

location_on Denmark ,  Denmark

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

ExoGenis is a DK/Singaporean biotech startup developing a new non-invasive delivery technology for sensitive biologics in cosmetology. Patent-protected, our platform makes advanced regenerative treatments accessible and safe

Highlights

  • Patent-protected dual-phase microneedle delivery platform
  • MVP in development with strong scientific validation underway
  • High-growth markets: skincare $150B+, exosomes + microneedles CAGR 10–20%
  • Hybrid B2B + D2C model with premium subscription potential
  • Experienced team with biotech, consulting and commercialization expertise

Overview

Target NZ$ 600,000
Minimum NZ$ 50,000
Investment Raised NZ$ 60,000
Previous Rounds NZ$ 60,000
Stage MVP/Finished Product
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects